Brought to you by 
Emergent, Univ. of Oxford form tuberculosis JV
26 Nov 2008
Executive Summary
Emergent BioSolutions (vaccines) and the University of Oxford have formed the Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture established to further develop MVA85A (AERAS485), a vaccine in development to prevent all forms of TB in all ages.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Emergent, Univ. of Oxford form tuberculosis JV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice